XTL Bio enters collaboration with Clalit

Israeli company XTL Biopharmaceuticals(TASE: XTL) has entered into a strategic collaboration framework agreement with Clalit Research Institute, the research arm of Clalit Health Services, and Mor Research Applications, the technology transfer office of the Clalit group.

The deal terms mean that, on XTL's request, the Institute will provide the company with clinical data and analyses which would be based on the Institute's database in connection with technologies that stem from inventions and patents of Clalit Health Services' physicians. The nature of the various clinical projects will be agreed upon by the company, the Institute and Mor in advance.

In return, XTL will pay the cost basis related to the Institute's activity in the collaboration framework of any project plus an additional 10% of the total royalties Mor is entitled pursuant to its agreements with the company in connection with each technology where rights were granted to XTL.